Skip to main content
53 search results for:

Monoclonal antibodies 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-10-2021 | Biosimilars | Adis Journal Club | Article
    BioDrugs

    Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective

    In spite of their considerable exposure and excellent safety record, many prescribers still have doubts on the safety and interchangeability of biosimilars, especially monoclonal antibodies (mAbs) and fusion proteins.

  2. 20-09-2017 | Colorectal cancer | Article

    Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis

    van Helden EJ et al. Cancer Metastasis Rev . 2017; 36: 395. doi:10.1007/s10555-017-9668-y

  3. 30-03-2022 | Immunotherapy | Adis Journal Club | Article
    BioDrugs

    Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy

    Gulley Abstract Cancer immunotherapy using monoclonal antibodies targeting immune checkpoints has undoubtedly revolutionized the cancer treatment landscape in the last decade.

  4. 15-09-2021 | HER2-positive breast cancer | Adis Journal Club | Article
    Drugs - Real World Outcomes

    Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database

    Authors: Maria Antonietta Barbieri, Emanuela Elisa Sorbara, Giuseppe Cicala, Vincenza Santoro, Paola Maria Cutroneo, Tindara Franchina & Edoardo Spina Abstract Background Anti-HER2 therapy has evolved in the last years and an important role in this transformation was that of monoclonal antibodies and tyrosine kinase inhibitors.

  5. 15-09-2021 | Non-small-cell lung cancer | News | Article

    No overall survival benefit with first-line bevacizumab–erlotinib in EGFR-mutant NSCLC

    Maemondo et al note that there are three ongoing phase 3 trials of VEGF- and VEGFR-targeted monoclonal antibodies with EGFR–tyrosine kinase inhibitors in patients with advanced EGFR -mutated NSCLC, namely the BEVERLY and CTONG 1509 trials of bevacizumab plus erlotinib and the RELAY trial of ramucirumab plus erlotinib.

  6. 15-03-2021 | Adis Journal Club | Article
    Drugs in R&D

    Bispecific Antibody Molecule Inhibits Tumor Cell Proliferation More Efficiently Than the Two-Molecule Combination

    Frejd, Kyu-Tae Kim, Jong-Seo Lee & Johan Rockberg  Abstract Background Monoclonal antibodies (mAbs) have proved to be a valuable tool for the treatment of different cancer types.

  7. 12-01-2021 | Breast cancer | News | Article

    Subcutaneous pertuzumab, trastuzumab noninferior to intravenous delivery

    Tan et al conclude: “Overall, the evidence shows that subcutaneous administration of monoclonal antibodies offers a faster, more convenient, and less invasive treatment option for HER2-positive breast cancer than do intravenous infusions.”

  8. 20-04-2020 | Prostate cancer | Brief review | Article

    Promising immunotherapies for advanced prostate cancer: playing catch-up?

    In chimeric antigen receptor T-cell (CAR-T) therapy, the specificity of antibodies is associated with the cytotoxic activity of T cells to target tumor cells.

  9. 10-12-2019 | Prostate cancer | News | Article

    Anti-STEAP1 antibody shows acceptable safety profile in mCRPC

    DSTP3086S, a humanized immunoglobulin G1 monoclonal antibody that targets six-transmembrane epithelial antigen of the prostate 1 has shown promising results in a phase 1 study of metastatic castration-resistant prostate cancer.

  10. 26-07-2017 | Teaser

    Transplantation for multiple myeloma

    This article provides an overview of the challenges in the care of patients with relapsed/refractory multiple myeloma, current and emerging treatment options, and the possible role of hematopoietic stem cell transplantation. Summary points Multiple myeloma (MM) is a disorder characterized by accumulation of malignant plasma cells in the bone marrow, hypercalcemia, monoclonal protein, and end organ damage. Newer generation proteasome inhibitors, monoclonal antibodies, and novel agents have been approved for patients with MM, which is increasing the life expectancy of the patients. However, hematopoietic stem cell transplantation still remains the cornerstone of treatment. Approximately 24 hours after completion of the preparative chemotherapy, patients undergoing autologous hematopoietic stem cell transplant (AHSCT) receive a reinfusion of peripheral blood progenitor cells followed by a period of pancytopenia. Red blood cell and platelet transfusions are administered as necessary while hematopoietic colony-stimulating factors are used to speed neutrophil engraftment, which occurs by day 10–11. Platelet counts are expected to recover to >20,000 by day 16. For myeloablative allogeneic hematopoietic stem cell transplant (allo-HSCT) the process is similar to AHSCT but myeloablative transplants require that patients receive high-dose chemotherapy with or without total body radiation, followed by donor stem cell infusion. Non-myeloablative-allogeneic transplantation remains investigational and its role needs to be validated in the era of novel agents. Syngeneic allogeneic transplants are from the identical twin donor and only a limited number of syngeneic transplants have been performed in MM. Transplantation helps in early reduction of clonal diversity and increases the likelihood of cure. Long-term follow-up studies show that AHSCT can achieve profound cytoreduction and cure a portion of patients even before the introduction of novel drugs. Novel immune therapeutic agents such as anti-CD38 antibodies, checkpoint blockade inhibitors, cellular therapies, and vaccines will be available soon and will enhance the anti-myeloma response without transplant-associated risks; such strategies will be complimentary and not a replacement for transplant. Jethava YS & van Rhee F. In:  Plasma Cell Dyscrasias . Edited by Roccaro AM & Ghobrial IM. Springer International Publishing, 2016. doi:10.1007/978-3-319-40320-5_13

  11. 26-07-2017 | Teaser

    Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity

    This article provides an overview of the challenges in the care of patients with relapsed/refractory multiple myeloma, current and emerging treatment options, and the possible role of hematopoietic stem cell transplantation. Summary points The use of modern therapies such as thalidomide, bortezomib, and lenalidomide coupled with upfront high-dose therapy and autologous stem cell transplant (ASCT) has resulted in improved survival in patients with newly diagnosed multiple myeloma (MM). However, patients with relapsed/refractory  MM (RRMM) present a therapeutic challenge as they often have poorer clinical outcomes. These patients have a median survival of only 1.5 years, and their clinical course is typified by decreasing response duration with an increasing number of salvage regimens. Current treatment standards for RRMM include (1) salvage chemotherapy, (2) salvage autologous stem cell transplant (ASCT), (3) allogeneic hematopoietic stem cell transplant (allo-SCT), and (4) post-transplant consolidation/maintenance therapy. Emerging therapies that target different mechanisms of action including immunotherapy, deacetylase inhibitors, monoclonal antibodies, and new proteasome inhibitors are promising and may change the therapeutic landscape in RRMM. Their favorable safety profiles as monotherapy in patients with RRMM will enable combinatorial use with ASCT/allo-SCT to further improve long-term disease control. Improvement in transplant outcomes has re-ignited a debate on the timing and possible role for salvage ASCT and allogeneic stem cell transplant in RRMM. As the treatment options for management of patients with RRMM become increasingly complex, physicians must consider both disease- and patient-related factors in choosing the appropriate therapeutic approach, with the goal of improving efficacy while minimizing toxicity. Enrolment of patients in clinical trials designed to answer unresolved issues in the treatment of patients with RRMM is highly recommended. Cornell RF & Kassim AA. Bone Marrow Transplant  2016; 51: 479–491. doi: 10.1038/bmt.2015.307

  12. 14-03-2017 | Lymphoma | Case report | Article

    SLL and CLL

    Monoclonal antibodies Anti-CD20 Rituximab Single agent rituximab in CLL produced an unimpressive ORR of 12% at doses used in non-Hodgkin lymphoma (NHL) [24].

  13. 24-05-2018 | Mesothelioma | News | Article

    Tremelimumab plus durvalumab active in unresectable mesothelioma

    They summarize in The Lancet Respiratory Medicine that “[t]he combined use of monoclonal antibodies targeting CTLA4 and PD-1 or PD-L1 might significantly affect the clinical course of patients with malignant mesothelioma.”

  14. 16-02-2018 | Multiple myeloma | News | Article

    Denosumab offers alternative to zoledronic acid in multiple myeloma

    Phase III study data show that the RANKL-targeting monoclonal antibody denosumab is noninferior to zoledronic acid for the prevention of bone disease in patients with newly diagnosed multiple myeloma.

  15. 14-03-2018 | Article

    Advisory board comment

    Rituximab has already been given to ALL patients with CD20-positive expression, and the sequential addition of immunotherapy with bispecific monoclonal antibodies such as blinatumomab may also be effective means of eliminating minimal residual disease with a potentially acceptable toxicity in older patients [12], although large-scale efficacy data are lacking.

  16. 15-11-2017 | Leukemia | Article

    Agents in Development for Childhood Acute Lymphoblastic Leukemia

    Maloney KW & Gore L. Pediatr Drugs 2017. doi:10.1007/s40272-017-0268-7

  17. 06-10-2017 | Follicular lymphoma | News | Article
    Editor's pick

    Obinutuzumab may improve follicular lymphoma outcome

    Discussing the findings, Armitage and Longo point out that the two treatments were given at different doses even though ”there was no evidence” to suggest that “the antibodies differ in target affinity.”

  18. 12-09-2017 | Treatment | Article

    A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

    Reynolds KL, Bedard PL, Lee SH et al. BMC Cancer 2017; 17:646. doi:10.1186/s12885-017-3641-6

  19. 12-09-2017 | Urothelial cancer | ESMO 2017 | Article
    ESMO 2017

    Ramucirumab plus docetaxel prolongs PFS in advanced urothelial cancers

    Adding ramucirumab to docetaxel significantly improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, show results from the phase III RANGE trial. Watch an interview with presenting author Daniel Petrylak here

  20. 30-06-2016 | Multiple myeloma | Article

    Novel agents in the treatment of multiple myeloma: a review about the future

    The authors review the plethora of novel agents currently in development or recently approved for the treatment of patients with multiple myeloma. Naymagon L & Abdul-Hay M. J Hematol Oncol 2016; 9: 52. doi:10.1186/s13045-016-0282-1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.